Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas

J Clin Oncol. 1996 Jan;14(1):85-94. doi: 10.1200/JCO.1996.14.1.85.

Abstract

Purpose: Experiments were designed to investigate the association between tumor leukocytic infiltrates with other pathologic and biologic variables in primary tumors and with prognosis, and to define the phenotype of the infiltrating leukocytes.

Patients and methods: A retrospective series of 1,207 primary breast carcinomas was studied according to different prognostic variables, including the presence of lymphoplasmacytic infiltrate (LPI). LPI was analyzed in association with other variables and survival. Additionally, a small prospective series of surgical specimens from 75 primary breast carcinomas with infiltrating leukocytes was tested by immunohistochemistry on frozen sections to phenotypically characterize the infiltrate, using anti-CD reagents, and the tumor, using anti-c-erbB-2 oncoprotein monoclonal antibody.

Results: In the retrospective series, menopausal status, nodal status, tumor size, stage, grade, and p185HER2 overexpression but not LPI were found to be associated with prognosis and maintained their prognostic significance in a multivariate analysis. LPI was significantly associated with some of these independent prognostic factors, such as tumor size (P = .03), stage (P = .004), grade III carcinomas (P < .000001), and overexpression of the p185HER2 (P < .000001). In some subgroups of patients in whom LPI was found more frequently, such as grade III cases or N- and c-erbB-2-positive cases, LPI was found to be indicative of a good prognosis (P = .008 and P = .03, respectively). Phenotypic analysis of the infiltrating leukocytes revealed a preponderance of macrophages in high-grade (P = .05) or c-erbB-2-positive (P = .008) tumors, whereas T cells constituted most of the infiltrate in the other tumors.

Conclusion: Our data demonstrate different leukocytic types in the infiltrate of breast tumors with different prognostic significance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / analysis
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Carcinoma, Ductal, Breast / immunology*
  • Carcinoma, Ductal, Breast / mortality
  • Carcinoma, Ductal, Breast / pathology
  • Carcinoma, Lobular / immunology*
  • Carcinoma, Lobular / mortality
  • Carcinoma, Lobular / pathology
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunophenotyping
  • Lymphocyte Subsets / pathology
  • Lymphocytes, Tumor-Infiltrating / pathology*
  • Macrophages / pathology
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Prospective Studies
  • Receptor, ErbB-2 / analysis*
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • T-Lymphocytes / pathology

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • Receptor, ErbB-2